Search studies using keywords
1,851 Studies in the database containing data with -log p ≥ 0 (showing 541-560)
Pages: << 21 22 23 24 25 26 27 28 29 30 >>
No data sets (in No Studies) added to Browser
Identifier Name Phenotype(s) Total p-values Related citationsAdd data sets to Browser Related data
HGVST1307 plus GWAS of IgG levels 
  • IgG levels
0
HGVST1308 plus GWAS of Sexual dysfunction (female) 
  • Sexual dysfunction (female) (Overall FSD)
  • Sexual dysfunction (female) (Lubrication)
  • Sexual dysfunction (female) (Arousal)
0
HGVST1309 plus GWAS of Hypothyroidism 
  • Hypothyroidism
0
HGVST1310 plus GWAS of Age-related macular degeneration (CNV) 
  • Age-related macular degeneration (CNV)
  • Age-related macular degeneration (GA)
0
HGVST1311 plus GWAS of Age-related macular degeneration 
  • Age-related macular degeneration
0
HGVST1312 plus GWAS of Coronary heart disease 
  • Coronary heart disease (CAD)
  • Coronary heart disease (LAD)
  • Coronary heart disease (RCA)
0
HGVST1298 plus GWAS of Head circumference (infant) 
  • Head circumference (infant)
0
HGVST1299 plus GWAS of Non-obstructive azoospermia 
  • Non-obstructive azoospermia
0
HGVST1300 plus GWAS of Asthma 
  • Asthma
0
HGVST1301 plus GWAS of Chronic lymphocytic leukemia 
  • Chronic lymphocytic leukemia
0
HGVST1302 plus GWAS of Vitiligo 
  • Vitiligo
0
HGVST1303 plus GWAS of Male-pattern baldness 
  • Male-pattern baldness
0
HGVST1304 plus GWAS of Cholelithiasis-related traits in sickle cell anemia 
  • Cholelithiasis-related traits in sickle cell anemia
0
HGVST1305 plus GWAS of Formal thought disorder in schizophrenia 
  • Formal thought disorder in schizophrenia
0
HGVST1306 plus GWAS of Response to tocilizumab in rheumatoid arthritis 
  • Response to tocilizumab in rheumatoid arthritis (CHAQ, EA, RF-)
  • Response to tocilizumab in rheumatoid arthritis (CHAQ , EA, RF-)
  • Response to tocilizumab in rheumatoid arthritis (CSJC , EA, RF-)
  • Response to tocilizumab in rheumatoid arthritis (CSJC, EA, RF+)
  • Response to tocilizumab in rheumatoid arthritis (CHAQ, RF-)
  • Response to tocilizumab in rheumatoid arthritis (CSJC , EA, RF+)
  • Response to tocilizumab in rheumatoid arthritis (CSJC, EA, RF-)
  • Response to tocilizumab in rheumatoid arthritis (CTJC, RF-)
  • Response to tocilizumab in rheumatoid arthritis (CSJC, RF-)
  • Response to tocilizumab in rheumatoid arthritis (CDAS28, EA, RF-)
  • Response to tocilizumab in rheumatoid arthritis (CTJC , EA, RF+)
  • Response to tocilizumab in rheumatoid arthritis (CTJC , EA, RF-)
  • Response to tocilizumab in rheumatoid arthritis (CSJC, RF+)
  • Response to tocilizumab in rheumatoid arthritis (CHAQ, RF+)
  • Response to tocilizumab in rheumatoid arthritis (CSJC , RF+)
0
HGVST1288 plus GWAS of Response to angiotensin II receptor blocker therapy 
  • Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) (AA)
  • Response to angiotensin II receptor blocker therapy (EA)
  • Response to angiotensin II receptor blocker therapy (AA)
  • Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) (EA)
0
HGVST1289 plus GWAS of Vitamin D levels 
  • Vitamin D levels
0
HGVST1290 plus GWAS of Immune response to anthrax vaccine 
  • Immune response to anthrax vaccine
0
HGVST1291 plus GWAS of Antipsychotic drug-induced weight gain 
  • Antipsychotic drug-induced weight gain
0
HGVST1292 plus GWAS of Asthma 
  • Asthma
0